Veradermics (NYSE:MANE) Stock Rating Upgraded by Wall Street Zen

Veradermics (NYSE:MANE) was upgraded by research analysts at Wall Street Zen from a “sell” rating to a “hold” rating in a report issued on Saturday.

Several other brokerages have also issued reports on MANE. Lifesci Capital initiated coverage on Veradermics in a report on Tuesday, June 16th. They set an “outperform” rating and a $135.00 price objective on the stock. B. Riley Financial began coverage on Veradermics in a report on Wednesday, July 15th. They issued a “buy” rating and a $170.00 target price for the company. Jefferies Financial Group upped their target price on Veradermics from $138.00 to $182.00 and gave the company a “buy” rating in a research report on Tuesday, July 7th. UBS Group set a $170.00 price target on Veradermics in a research note on Wednesday, July 15th. Finally, Citigroup lifted their price target on Veradermics from $135.00 to $160.00 and gave the stock a “buy” rating in a research report on Thursday, July 16th. Seven analysts have rated the stock with a Buy rating, one has assigned a Hold rating and one has given a Sell rating to the stock. According to data from MarketBeat.com, the company currently has a consensus rating of “Moderate Buy” and an average target price of $153.00.

Veradermics Stock Performance

Shares of Veradermics stock opened at $105.05 on Friday. The firm has a fifty day moving average of $108.02. The firm has a market cap of $4.39 billion and a PE ratio of -79.58. Veradermics has a 12-month low of $32.00 and a 12-month high of $131.24.

Veradermics (NYSE:MANE) last announced its quarterly earnings results on Tuesday, May 12th. The company reported ($1.32) EPS for the quarter, missing the consensus estimate of ($0.56) by ($0.76).

About Veradermics

We are a dermatologist-founded, late clinical-stage biopharmaceutical company focused on developing innovative therapeutics to address pervasive treatment challenges in highly prevalent aesthetic and dermatological conditions. Our initial focus is developing better treatments for pattern hair loss, or PHL, a condition affecting approximately 50 million men and 30 million women in the United States. Current PHL treatment options are limited and therefore are consistently plagued with high rates of treatment failure, patient dissatisfaction and treatment discontinuation.